These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 15056149)

  • 41. The long-term host response to liquid silicone injected during soft tissue augmentation procedures: a microscopic appraisal.
    Zappi E; Barnett JG; Zappi M; Barnett CR
    Dermatol Surg; 2007 Dec; 33 Suppl 2():S186-92; discussion S192. PubMed ID: 18086057
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A retrospective study on liquid injectable silicone for lip augmentation: long-term results and patient satisfaction.
    Moscona RA; Fodor L
    J Plast Reconstr Aesthet Surg; 2010 Oct; 63(10):1694-8. PubMed ID: 19892612
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Single-slice computed tomography and anthropometric skinfold analysis for evaluation of facial lipoatrophy in HIV-infected patients.
    Padilla S; Gallego JA; Masiá M; Gutiérrez F
    Clin Infect Dis; 2004 Dec; 39(12):1848-51. PubMed ID: 15578410
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Six-year experience using 1,000-centistoke silicone oil in 916 patients for soft-tissue augmentation in a private practice setting.
    Hevia O
    Dermatol Surg; 2009 Oct; 35 Suppl 2():1646-52. PubMed ID: 19807759
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HIV-associated facial lipoatrophy--review of current therapy options.
    Bechara FG; Sand M; Potthoff A; Altmeyer P; Brockmeyer NH;
    Eur J Med Res; 2008 Mar; 13(3):93-9. PubMed ID: 18499554
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Poly-L-lactic acid injection for HIV-associated facial lipoatrophy: treatment principles, case studies, and literature review.
    Kates LC; Fitzgerald R
    Aesthet Surg J; 2008; 28(4):397-403. PubMed ID: 19083552
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Treatment of HIV facial lipoatrophy with a submalar porous polyethylene implant (Medpor)].
    Claude O; Domergue Than Trong E; Blanc R; Ascher B; Bagot M; Meningaud JP; Lantieri L
    Ann Chir Plast Esthet; 2009 Feb; 54(1):21-8. PubMed ID: 19042066
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and efficacy of one-step rehabilitation of human immunodeficiency virus-related facial lipoatrophy using an injectable calcium hydroxylapatite dermal filler.
    Rauso R; Curinga G; Rusciani A; Colella G; Amore R; Tartaro G
    Dermatol Surg; 2013 Dec; 39(12):1887-94. PubMed ID: 24299576
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and efficacy of poly-L-lactic acid injections in persons with HIV-associated lipoatrophy: the US experience.
    Mest DR; Humble G
    Dermatol Surg; 2006 Nov; 32(11):1336-45. PubMed ID: 17083585
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Polymethylmethacrylate facial implant: a successful personal experience in Brazil for more than 9 years.
    Carvalho Costa IM; Salaro CP; Costa MC
    Dermatol Surg; 2009 Aug; 35(8):1221-7. PubMed ID: 19438669
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lipoatrophic men 44 months after the diagnosis of lipoatrophy are less lipoatrophic but more hypertensive.
    Bergersen BM; Sandvik L; Ellingsen I; Bruun JN
    HIV Med; 2005 Jul; 6(4):260-7. PubMed ID: 16011531
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy.
    Moyle GJ; Brown S; Lysakova L; Barton SE
    HIV Med; 2006 Apr; 7(3):181-5. PubMed ID: 16494632
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Treatment of facial lipoatrophy by lipofilling in HIV infected patients: retrospective study on 317 patients on 9 years].
    Uzzan C; Boccara D; Lacheré A; Mimoun M; Chaouat M
    Ann Chir Plast Esthet; 2012 Jun; 57(3):210-6. PubMed ID: 22218365
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical trial of a novel filler material for soft tissue augmentation of the face containing synthetic calcium hydroxylapatite microspheres.
    Roy D; Sadick N; Mangat D
    Dermatol Surg; 2006 Sep; 32(9):1134-9. PubMed ID: 16970693
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Persistence of lipoatrophy after a four-year long interruption of antiretroviral therapy for HIV1 infection: case report.
    Parruti G; Toro GM
    BMC Infect Dis; 2005 Oct; 5():80. PubMed ID: 16202141
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Short-term results of incremental penile girth enhancement using liquid injectable silicone: words of praise for a change.
    Yacobi Y; Tsivian A; Grinberg R; Kessler O
    Asian J Androl; 2007 May; 9(3):408-13. PubMed ID: 17486283
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Radiographic and computed tomographic studies of calcium hydroxylapatite for treatment of HIV-associated facial lipoatrophy and correction of nasolabial folds.
    Carruthers A; Liebeskind M; Carruthers J; Forster BB
    Dermatol Surg; 2008 Jun; 34 Suppl 1():S78-84. PubMed ID: 18547186
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Industrial-grade silicone injections causing intermittent bilateral malar swelling: review of safety and efficacy of techniques and products available.
    Seward AC; Meara DJ
    J Oral Maxillofac Surg; 2013 Jul; 71(7):1245-8. PubMed ID: 23522770
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Facial lipohypertrophy in HIV-infected subjects who underwent autologous fat tissue transplantation.
    Guaraldi G; De Fazio D; Orlando G; Murri R; Wu A; Guaraldi P; Esposito R
    Clin Infect Dis; 2005 Jan; 40(2):e13-5. PubMed ID: 15655734
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Management options for facial lipoatrophy.
    Cofrancesco J; Brown T; Martins CR
    AIDS Read; 2004 Dec; 14(12):639-40, 645-50. PubMed ID: 15619779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.